Table 1.
Demographics and clinical characteristics of psoriasis patients and healthy controls.
Fig 1.
mtDNA-CN in psoriasis patients and healthy controls.
The mtDNA-CN was quantified by real-time qPCR in peripheral blood buffy coat samples from patients with psoriasis (n = 56) and healthy controls (n = 44). A: Bar graph of data expressed as the mean ± standard deviation (SD). B: Dot plot of data.
Fig 2.
Relationship of mtDNA-CN with disease duration.
The patients were sub-divided into two groups based on disease duration as <10 years (n = 23) and >10 years (n = 33). A: Bar graph of data expressed as the mean ± standard deviation (SD). B: Dot plot of data.
Fig 3.
Relationship of mtDNA-CN with the disease severity.
The patients were sub-divided based on PASI scores into two groups as mild (n = 23) and moderate-to-severe (n = 33). A: Bar graph of data expressed as the mean ± standard deviation (SD). B: Dot plot of data.
Table 2.
Correlation between mtDNA-CN number and clinical variables in psoriasis patients.
Fig 4.
ROC curve was generated to evaluate the diagnostic value of mtDNA-CN as a biomarker for psoriasis. The AUC for discriminating psoriasis patients from healthy controls was 0.84 (95% CI: 0.694–0.977, P = 0.002).